Clinical effect analysis of sodium hyaluronate combined with recombinant human epidermal growth factor in the treatment of xerophthalmia after senile cataract surgery

ObjectiveTo observe the clinical effects of sodium hyaluronate combined with recombinant human epidermal growth factor(rhEGF) in the treatment of xerophthalmia after senile cataract surgery.

MethodsNinety xerophthalmia patients after phacoemulsification were randomly divided into the observation group and control group(45 cases in each group).The control group was treated with sodium hyaluronate eye drops on the basis of anti-inflammatory drugs, 1 drop/time, 3 times/day.The observation group was additionally treated with eye drops, 1 drop/time, 3 times/day based on the control group.The treatment time in two groups was 28 days.The tear film break-up time(BUT) test, Schirmer I test(SITI), corneal fluorescent staining(FL) and symptom score in two groups were performed before treatment, after 14 and 28 days of treatment.The levels of interleukin-6(IL-6) and hypersensitive C reactive protein(hs-CRP) in tears of two groups were detected.

ResultsWith the progress of treatment time, the BUT and SIT values in two groups significantly increased(P < 0.05), and the FL, symptom score, levels of IL-6 and hs-CRP significantly decreased(P < 0.05).The BUT and SIT values in observation group after 14 days and 28 days of treatment were significantly higher than those in control group(P < 0.01).The FL value, symptom score, levels of IL-6 and hsCRP in observation group after 14 and 28 days of treatment were significantly lower than those in control group(P < 0.01).

ConclusionsThe combination of sodium hyaluronate and rhEGF in the treatment of xerophthalmia after senile cataract surgery is effective.